Clinical trials
Brain Metastases From Breast Cancer clinical trials
Below are recruiting brain metastases from breast cancer clinical trials, each written for real people, not researchers. We’re tracking 364 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Chicago, IllinoisAges 18–99 - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT04923542RecruitingPhase 1/Phase 2
Targeted drug plus focused brain radiation for breast cancer
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Tampa, FloridaAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04689048RecruitingPhase 1
Testing a brain scan tracer for large, staged brain metastases
This Phase 1 study tests an injected radioactive tracer (18F-fluciclovine) to improve how doctors image and assess large brain metastases. It may help guide treatment when you’re receiving staged stereotactic radiosurgery (focused radiation in steps).
Miami, FloridaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Anchorage, AlaskaAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
San Carlos, CaliforniaAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Norwalk, ConnecticutAges 18 years+ - NCT02830724RecruitingPhase 1/Phase 2
CAR T therapy using blood immune cells for CD70 cancers
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
Bethesda, MarylandAges 18–72 - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT02732860Recruiting
Test your tumor’s drug response using a lab model
This trial grows a lab model from your own tumor tissue (or resected tissue) to predict which drugs might work best. It’s meant to match investigational treatments to your specific tumor biology.
Toronto, OntarioAges 18 years+ - NCT02747303RecruitingPhase 2
Focused radiation for 1 to 5 brain metastases without surgery
This Phase 2 study tests a precise, no-head-frame radiation technique to treat brain metastases. It may help by aiming radiation tightly at the tumors while limiting exposure to nearby healthy brain.
Chicago, IllinoisAges 18 years+ - NCT02390518RecruitingPhase 1
Tested different radiation doses for brain metastases
This Phase 1 study tests how to safely give focused radiation (SRS) at different doses to people with brain metastases. It aims to find a dose level that works well while limiting side effects.
Salt Lake City, UtahAges 18 years+ - NCT07817082RecruitingPhase 2
A new drug for her2 ultra-low advanced breast cancer
This study tests a new targeted drug (SHR-A1811) for breast cancer that has very low HER2 levels. The drug is designed to attack cancer cells with this specific marker, and the study aims to see if it can help slow the cancer's growth.
TianjinAges 18–75
Hear when a new Brain Metastases From Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from breast cancer?
- Yes. Clin2 currently lists 364 recruiting brain metastases from breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Brain Metastases From Solid Tumors
- Liver Metastases From Colorectal Cancer
- Peritoneal Metastases From Colorectal Cancer
- Brain Metastases From Extra-cranial Solid Tumors
- Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.